Show simple item record

dc.contributor.authorPhillips, Lawrence M.
dc.contributor.authorHachamovitch, Rory
dc.contributor.authorBerman, Daniel S.
dc.contributor.authorIskandrian, Ami E.
dc.contributor.authorMin, James K.
dc.contributor.authorPicard, Michael Howard
dc.contributor.authorKwong, Raymond Yan-Kit
dc.contributor.authorFriedrich, Matthias G.
dc.contributor.authorScherrer-Crosbie, Marielle
dc.contributor.authorHayes, Sean W.
dc.contributor.authorSharir, Tali
dc.contributor.authorGosselin, Gilbert
dc.contributor.authorMazzanti, Marco
dc.contributor.authorSenior, Roxy
dc.contributor.authorBeanlands, Rob
dc.contributor.authorSmanio, Paola
dc.contributor.authorGoyal, Abhi
dc.contributor.authorAl-Mallah, Mouaz
dc.contributor.authorReynolds, Harmony
dc.contributor.authorStone, Gregg W.
dc.contributor.authorMaron, David J.
dc.contributor.authorShaw, Leslee J.
dc.date.accessioned2016-10-19T19:15:09Z
dc.date.issued2013
dc.identifier.citationPhillips, Lawrence M., Rory Hachamovitch, Daniel S. Berman, Ami E. Iskandrian, James K. Min, Michael H. Picard, Raymond Y. Kwong, et al. 2013. Lessons Learned from MPI and Physiologic Testing in Randomized Trials of Stable Ischemic Heart Disease: COURAGE, BARI 2D, FAME, and ISCHEMIA. J. Nucl. Cardiol. 20, no. 6: 969–975. doi:10.1007/s12350-013-9773-4.en_US
dc.identifier.issn1071-3581en_US
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:29048902
dc.description.abstractThere is a preponderance of evidence that, in the setting of an acute coronary syndrome, an invasive approach using coronary revascularization has a morbidity and mortality benefit. However, recent stable ischemic heart disease (SIHD) randomized clinical trials testing whether the addition of coronary revascularization to guideline-directed medical therapy (GDMT) reduces death or major cardiovascular events have been negative. Based on the evidence from these trials, the primary role of GDMT as a front line medical management approach has been clearly defined in the recent SIHD clinical practice guideline; the role of prompt revascularization is less precisely defined. Based on data from observational studies, it has been hypothesized that there is a level of ischemia above which a revascularization strategy might result in benefit regarding cardiovascular events. However, eligibility for recent negative trials in SIHD has mandated at most minimal standards for ischemia. An ongoing randomized trial evaluating the effectiveness of randomization of patients to coronary angiography and revascularization as compared to no coronary angiography and GDMT in patients with moderate-severe ischemia will formally test this hypothesis. The current review will highlight the available evidence including a review of the published and ongoing SIHD trials.en_US
dc.language.isoen_USen_US
dc.publisherSpringer Science + Business Mediaen_US
dc.relation.isversionofdoi:10.1007/s12350-013-9773-4en_US
dc.relation.hasversionhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3954506/en_US
dash.licenseLAA
dc.subjectmyocardial perfusion imagingen_US
dc.subjectischemiaen_US
dc.subjectcoronary artery diseaseen_US
dc.subjectclinical trialsen_US
dc.titleLessons learned from MPI and physiologic testing in randomized trials of stable ischemic heart disease: COURAGE, BARI 2D, FAME, and ISCHEMIAen_US
dc.typeJournal Articleen_US
dc.description.versionAccepted Manuscripten_US
dc.relation.journalJournal of Nuclear Cardiologyen_US
dash.depositing.authorPicard, Michael Howard
dc.date.available2016-10-19T19:15:09Z
dc.identifier.doi10.1007/s12350-013-9773-4*
dash.authorsorderedfalse
dash.contributor.affiliatedKwong, Raymond
dash.contributor.affiliatedScherrer-Crosbie, Marielle
dash.contributor.affiliatedPicard, Michael


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record